Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

Dunn, 2004, The three Es of cancer immunoediting, Annu Rev Immunol, 22, 329, 10.1146/annurev.immunol.22.012703.104803

Mantovani, 2008, Tumour immunity: effector response to tumour and role of the microenvironment, Lancet, 371, 771, 10.1016/S0140-6736(08)60241-X

Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486

Pages, 2005, Effector memory T cells, early metastasis, and survival in colorectal cancer, N Engl J Med, 353, 2654, 10.1056/NEJMoa051424

Laghi, 2009, CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study, Lancet Oncol, 10, 877, 10.1016/S1470-2045(09)70186-X

Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, 348, 203, 10.1056/NEJMoa020177

Clemente, 1996, Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, 77, 1303, 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5

Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, 29, 235, 10.1146/annurev-immunol-031210-101324

Mahmoud, 2011, Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, J Clin Oncol, 29, 1949, 10.1200/JCO.2010.30.5037

Mantovani, 2004, Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression, Eur J Cancer, 40, 1660, 10.1016/j.ejca.2004.03.016

Pollard, 2004, Tumour-educated macrophages promote tumour progression and metastasis, Nat Rev Cancer, 4, 71, 10.1038/nrc1256

Talmadge, 2007, Inflammatory cell infiltration of tumors: Jekyll or Hyde, Cancer Metastasis Rev, 26, 373, 10.1007/s10555-007-9072-0

Martinez, 2009, Alternative activation of macrophages: an immunologic functional perspective, Annu Rev Immunol, 27, 451, 10.1146/annurev.immunol.021908.132532

DeNardo, 2009, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16, 91, 10.1016/j.ccr.2009.06.018

Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014

Wang, 2010, Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions, Cell Cycle, 9, 4824, 10.4161/cc.9.24.14322

Gordon, 2005, Monocyte and macrophage heterogeneity, Nat Rev Immunol, 5, 953, 10.1038/nri1733

Mantovani, 2004, The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol, 25, 677, 10.1016/j.it.2004.09.015

Hamilton, 2008, Colony-stimulating factors in inflammation and autoimmunity, Nat Rev Immunol, 8, 533, 10.1038/nri2356

Auffray, 2009, Blood monocytes: development, heterogeneity, and relationship with dendritic cells, Annu Rev Immunol, 27, 669, 10.1146/annurev.immunol.021908.132557

Stout, 2009, Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages, J Leukoc Biol, 86, 1105, 10.1189/jlb.0209073

Murray, 2011, Obstacles and opportunities for understanding macrophage polarization, J Leukoc Biol, 89, 557, 10.1189/jlb.0710409

Gordon, 2003, Alternative activation of macrophages, Nat Rev Immunol, 3, 23, 10.1038/nri978

Stein, 1992, Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation, J Exp Med, 176, 287, 10.1084/jem.176.1.287

Mantovani, 1992, The origin and function of tumor-associated macrophages, Immunol Today, 13, 265, 10.1016/0167-5699(92)90008-U

Goerdt, 1999, Other functions, other genes: alternative activation of antigen-presenting cells, Immunity, 10, 137, 10.1016/S1074-7613(00)80014-X

Allavena, 2008, The yin–yang of tumor-associated macrophages in neoplastic progression and immune surveillance, Immunol Rev, 222, 155, 10.1111/j.1600-065X.2008.00607.x

Pollard, 2009, Trophic macrophages in development and disease, Nat Rev Immunol, 9, 259, 10.1038/nri2528

Mantovani, 2005, Macrophage polarization comes of age, Immunity, 23, 344, 10.1016/j.immuni.2005.10.001

Gordon, 2010, Alternative activation of macrophages: mechanism and functions, Immunity, 32, 593, 10.1016/j.immuni.2010.05.007

Clark, 2007, Dynamics of the immune reaction to pancreatic cancer from inception to invasion, Cancer Res, 67, 9518, 10.1158/0008-5472.CAN-07-0175

Bottazzi, 1983, Regulation of the macrophage content of neoplasms by chemoattractants, Science, 220, 210, 10.1126/science.6828888

Zachariae, 1990, Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line, J Exp Med, 171, 2177, 10.1084/jem.171.6.2177

Kacinski, 1995, CSF-1 and its receptor in ovarian, endometrial and breast cancer, Ann Med, 27, 79, 10.3109/07853899509031941

Smith, 1995, The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma, Clin Cancer Res, 1, 313

Mantovani, 2002, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, 23, 549, 10.1016/S1471-4906(02)02302-5

Sica, 2006, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy, Eur J Cancer, 42, 717, 10.1016/j.ejca.2006.01.003

Van Ginderachter, 2006, Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion, Immunobiology, 211, 487, 10.1016/j.imbio.2006.06.002

Movahedi, 2010, Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes, Cancer Res, 70, 5728, 10.1158/0008-5472.CAN-09-4672

Solinas, 2010, Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility, J Immunol, 185, 642, 10.4049/jimmunol.1000413

Mantovani, 2006, Role of tumor-associated macrophages in tumor progression and invasion, Cancer Metastasis Rev, 25, 315, 10.1007/s10555-006-9001-7

Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205

DeNardo, 2008, Immune cells as mediators of solid tumor metastasis, Cancer Metastasis Rev, 27, 11, 10.1007/s10555-007-9100-0

Biswas, 2006, A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation), Blood, 107, 2112, 10.1182/blood-2005-01-0428

Ojalvo, 2010, Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors, J Immunol, 184, 702, 10.4049/jimmunol.0902360

Hagemann, 2009, Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB, Blood, 113, 3139, 10.1182/blood-2008-12-172825

Allavena, 2010, Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages, Clin Dev Immunol, 2010, 547179, 10.1155/2010/547179

Lewis, 2006, Distinct role of macrophages in different tumor microenvironments, Cancer Res, 66, 605, 10.1158/0008-5472.CAN-05-4005

Stout, 2005, Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes, Immunol Rev, 205, 60, 10.1111/j.0105-2896.2005.00260.x

Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322

Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0

Aggarwal, 2006, Inflammation and cancer: how hot is the link?, Biochem Pharmacol, 72, 1605, 10.1016/j.bcp.2006.06.029

Li, 2011, The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment, Cancer Cell, 19, 429, 10.1016/j.ccr.2011.03.018

Karin, 2005, NF-kappaB: linking inflammation and immunity to cancer development and progression, Nat Rev Immunol, 5, 749, 10.1038/nri1703

Colotta, 2009, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, Carcinogenesis, 30, 1073, 10.1093/carcin/bgp127

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Pikarsky, 2004, NF-kappaB functions as a tumour promoter in inflammation-associated cancer, Nature, 431, 461, 10.1038/nature02924

Mancino, 2010, Nuclear factor-kappaB and tumor-associated macrophages, Clin Cancer Res, 16, 784, 10.1158/1078-0432.CCR-09-1015

Biswas, 2010, NF-kappaB as a central regulator of macrophage function in tumors, J Leukoc Biol, 88, 877, 10.1189/jlb.0310153

Bianchi, 2007, High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity, Immunol Rev, 220, 35, 10.1111/j.1600-065X.2007.00574.x

Balkwill, 2009, Tumour necrosis factor and cancer, Nat Rev Cancer, 9, 361, 10.1038/nrc2628

Greten, 2004, IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer, Cell, 118, 285, 10.1016/j.cell.2004.07.013

Grivennikov, 2009, IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer Cell, 15, 103, 10.1016/j.ccr.2009.01.001

Maeda, 2005, IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis, Cell, 121, 977, 10.1016/j.cell.2005.04.014

Naugler, 2007, Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production, Science, 317, 121, 10.1126/science.1140485

Rius, 2008, NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha, Nature, 453, 807, 10.1038/nature06905

Fang, 2009, Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia, Blood, 114, 844, 10.1182/blood-2008-12-195941

Lamb, 2003, A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer, Cell, 114, 323, 10.1016/S0092-8674(03)00570-1

Liu, 2010, Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells, J Biol Chem, 285, 27429, 10.1074/jbc.M110.142752

Fukuda, 2011, Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression, Cancer Cell, 19, 441, 10.1016/j.ccr.2011.03.002

Lesina, 2011, Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer, Cancer Cell, 19, 456, 10.1016/j.ccr.2011.03.009

Mantovani, 2010, The chemokine system in cancer biology and therapy, Cytokine Growth Factor Rev, 21, 27, 10.1016/j.cytogfr.2009.11.007

Lazennec, 2010, Chemokines and chemokine receptors: new insights into cancer-related inflammation, Trends Mol Med, 16, 133, 10.1016/j.molmed.2010.01.003

Balkwill, 2004, Cancer and the chemokine network, Nat Rev Cancer, 4, 540, 10.1038/nrc1388

Adair-Kirk, 2005, A chemotactic peptide from laminin alpha 5 functions as a regulator of inflammatory immune responses via TNF alpha-mediated signaling, J Immunol, 174, 1621, 10.4049/jimmunol.174.3.1621

Kim, 2009, Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis, Nature, 457, 102, 10.1038/nature07623

Jiang, 2005, Regulation of lung injury and repair by Toll-like receptors and hyaluronan, Nat Med, 11, 1173, 10.1038/nm1315

Kalluri, 2006, Fibroblasts in cancer, Nat Rev Cancer, 6, 392, 10.1038/nrc1877

Ingman, 2006, Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland, Dev Dyn, 235, 3222, 10.1002/dvdy.20972

Moussai, 2011, The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C, J Invest Dermatol, 131, 229, 10.1038/jid.2010.266

Joyce, 2009, Microenvironmental regulation of metastasis, Nat Rev Cancer, 9, 239, 10.1038/nrc2618

Bollrath, 2009, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis, Cancer Cell, 15, 91, 10.1016/j.ccr.2009.01.002

Ribatti, 2009, The role of monocytes–macrophages in vasculogenesis in multiple myeloma, Leukemia, 23, 1535, 10.1038/leu.2009.55

Murdoch, 2008, The role of myeloid cells in the promotion of tumour angiogenesis, Nat Rev Cancer, 8, 618, 10.1038/nrc2444

Baeriswyl, 2009, The angiogenic switch in carcinogenesis, Semin Cancer Biol, 19, 329, 10.1016/j.semcancer.2009.05.003

Du, 2008, HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion, Cancer Cell, 13, 206, 10.1016/j.ccr.2008.01.034

Zumsteg, 2009, Myeloid cells contribute to tumor lymphangiogenesis, PLoS ONE, 4, e7067, 10.1371/journal.pone.0007067

Lewis, 2000, Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas, J Pathol, 192, 150, 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G

De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002

Kessenbrock, 2010, Matrix metalloproteinases: regulators of the tumor microenvironment, Cell, 141, 52, 10.1016/j.cell.2010.03.015

Recalcati, 2010, Differential regulation of iron homeostasis during human macrophage polarized activation, Eur J Immunol, 40, 824, 10.1002/eji.200939889

Cairo, 2011, Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype, Trends Immunol, 32, 241, 10.1016/j.it.2011.03.007

Mason, 2011, Proteolytic networks in cancer, Trends Cell Biol, 21, 228, 10.1016/j.tcb.2010.12.002

Wyckoff, 2007, Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors, Cancer Res, 67, 2649, 10.1158/0008-5472.CAN-06-1823

Pollard, 2008, Macrophages define the invasive microenvironment in breast cancer, J Leukoc Biol, 84, 623, 10.1189/jlb.1107762

Gocheva, 2010, IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion, Genes Dev, 24, 241, 10.1101/gad.1874010

Chen, 2011, CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3, Cancer Cell, 19, 541, 10.1016/j.ccr.2011.02.006

Schor, 2003, Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells, Cancer Res, 63, 8827

Du, 2010, Expression of snail in epidermal keratinocytes promotes cutaneous inflammation and hyperplasia conducive to tumor formation, Cancer Res, 70, 10080, 10.1158/0008-5472.CAN-10-0324

Sica, 2000, Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages, J Immunol, 164, 762, 10.4049/jimmunol.164.2.762

Marigo, 2008, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells, Immunol Rev, 222, 162, 10.1111/j.1600-065X.2008.00602.x

Yu, 2009, STATs in cancer inflammation and immunity: a leading role for STAT3, Nat Rev Cancer, 9, 798, 10.1038/nrc2734

Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat Rev Immunol, 9, 162, 10.1038/nri2506

Bianchi, 2011, Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells, Histol Histopathol, 26, 941

Bronte, 2003, L-arginine metabolism in myeloid cells controls T-lymphocyte functions, Trends Immunol, 24, 302, 10.1016/S1471-4906(03)00132-7

Sica, 2007, Altered macrophage differentiation and immune dysfunction in tumor development, J Clin Invest, 117, 1155, 10.1172/JCI31422

Bronte, 2005, Regulation of immune responses by L-arginine metabolism, Nat Rev Immunol, 5, 641, 10.1038/nri1668

Schutyser, 2002, Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma, J Biol Chem, 277, 24584, 10.1074/jbc.M112275200

Steinman, 2003, Tolerogenic dendritic cells, Annu Rev Immunol, 21, 685, 10.1146/annurev.immunol.21.120601.141040

Banchereau, 2005, Dendritic cells as therapeutic vaccines against cancer, Nat Rev Immunol, 5, 296, 10.1038/nri1592

Bingle, 2002, The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, J Pathol, 196, 254, 10.1002/path.1027

Forssell, 2007, High macrophage infiltration along the tumor front correlates with improved survival in colon cancer, Clin Cancer Res, 13, 1472, 10.1158/1078-0432.CCR-06-2073

Ohno, 2003, The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients, Anticancer Res, 23, 5015

Sconocchia, 2011, Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma, Int J Cancer, 128, 2663, 10.1002/ijc.25609

Ohtani, 1997, Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity?, Lab Invest, 77, 231

Sugita, 2002, Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions, Jpn J Cancer Res, 93, 320, 10.1111/j.1349-7006.2002.tb02175.x

Ohtaki, 2010, Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma, J Thorac Oncol, 5, 1507, 10.1097/JTO.0b013e3181eba692

Beck, 2009, The macrophage colony-stimulating factor 1 response signature in breast carcinoma, Clin Cancer Res, 15, 778, 10.1158/1078-0432.CCR-08-1283

Finak, 2008, Stromal gene expression predicts clinical outcome in breast cancer, Nat Med, 14, 518, 10.1038/nm1764

Ghassabeh, 2006, Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions, Blood, 108, 575, 10.1182/blood-2005-04-1485

Lenz, 2008, Stromal gene signatures in large-B-cell lymphomas, N Engl J Med, 359, 2313, 10.1056/NEJMoa0802885

Steidl, 2010, Tumor-associated macrophages and survival in classic Hodgkin's lymphoma, N Engl J Med, 362, 875, 10.1056/NEJMoa0905680

De Palma, 2007, Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications, Trends Immunol, 28, 519, 10.1016/j.it.2007.09.004

Welford, 2011, TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice, J Clin Invest, 121, 1969, 10.1172/JCI44562

Ferrara, 2010, Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis, Curr Opin Hematol, 17, 219

Shojaei, 2008, Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells, Cancer Res, 68, 5501, 10.1158/0008-5472.CAN-08-0925

Shojaei, 2007, Bv8 regulates myeloid-cell-dependent tumour angiogenesis, Nature, 450, 825, 10.1038/nature06348

Lin, 2001, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy, J Exp Med, 193, 727, 10.1084/jem.193.6.727

Aharinejad, 2009, Targeting stromal-cancer cell interactions with siRNAs, Methods Mol Biol, 487, 243

Zeisberger, 2006, Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach, Br J Cancer, 95, 272, 10.1038/sj.bjc.6603240

Brown, 2009, Anti-tumour effects of bisphosphonates – what have we learned from in vivo models?, Curr Cancer Drug Targets, 9, 807, 10.2174/156800909789760339

Morgan, 2010, First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, Lancet, 376, 1989, 10.1016/S0140-6736(10)62051-X

Zhang, 2010, Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects, Clin Cancer Res, 16, 3420, 10.1158/1078-0432.CCR-09-2904

Martin, 2010, Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma, Cancer Res, 70, 8607, 10.1158/0008-5472.CAN-10-0850

Allavena, 2005, Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production, Cancer Res, 65, 2964, 10.1158/0008-5472.CAN-04-4037

D'Incalci, 2010, A review of trabectedin (ET-743): a unique mechanism of action, Mol Cancer Ther, 9, 2157, 10.1158/1535-7163.MCT-10-0263

Germano, 2010, Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells, Cancer Res, 70, 2235, 10.1158/0008-5472.CAN-09-2335

Grosso, 2007, Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study, Lancet Oncol, 8, 595, 10.1016/S1470-2045(07)70175-4

Carter, 2010, Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer, Drugs, 70, 355, 10.2165/11202860-000000000-00000

Monk, 2010, Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer, J Clin Oncol, 28, 3107, 10.1200/JCO.2009.25.4037

Loberg, 2007, Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo, Cancer Res, 67, 9417, 10.1158/0008-5472.CAN-07-1286

Li, 2009, A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone, Cancer Res, 69, 1685, 10.1158/0008-5472.CAN-08-2164

Popivanova, 2009, Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice, Cancer Res, 69, 7884, 10.1158/0008-5472.CAN-09-1451

Pelegrin, 2009, Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates, EMBO J, 28, 2114, 10.1038/emboj.2009.163

Guiducci, 2005, Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection, Cancer Res, 65, 3437, 10.1158/0008-5472.CAN-04-4262

Cappello, 2004, CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity, J Leukoc Biol, 75, 135, 10.1189/jlb.0403146

Buhtoiarov, 2011, Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages, Immunology, 132, 226, 10.1111/j.1365-2567.2010.03357.x

Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443

Juarez, 2002, Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain, Cancer Res, 62, 5344

Olsson, 2004, A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization, Cancer Res, 64, 599, 10.1158/0008-5472.CAN-03-1941

Rolny, 2011, HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF, Cancer Cell, 19, 31, 10.1016/j.ccr.2010.11.009

Watkins, 2007, IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo, J Immunol, 178, 1357, 10.4049/jimmunol.178.3.1357

Karin, 2006, Nuclear factor-kappaB in cancer development and progression, Nature, 441, 431, 10.1038/nature04870